Clinical trial NCT05067231: CARBON: UAB Cardiovascular Research Biobank
Official title: UAB Cardiovascular Research Biobank
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Natriuretic Peptides
Cardiovascular Diseases
Hypertension
Diabetes
Obesity
Keywords: Natriuretic Peptides
Cardiovascular Diseases
Hypertension
Diabetes
Obesity
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
First posted: 2021-10-05
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals living in the Birmingham area will be enrolled through the University of Alabama at Birmingham campus. We will also enroll individuals who are associated with the University of Alabama at Birmingham.

Brief summary: The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains biological materials, such as DNA samples, in addition to health and personal information on a large number of people over time. It will be set up so that it can be used in the future as a resource for researchers undertaking a wide range of medical research.

Detailed description: The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains pertinent genetic, health, and biological samples such as blood derived from a large-scale population. Researchers may use disease correlates and predictors identified from the genetic, health, and personal information contained in the Biobank as a resource to investigate cardiovascular disease, hypertension, diabetes, and a myriad of other disorders. Through these studies, researchers may identify the progression of risk factors in certain diseases and help develop novel strategies to detect, treat, or prevent such diseases. In addition, the Biobank serves as a valuable tool to assess how certain treatments may respond differently to individuals as a result of genotypic differences.

The investigators have demonstrated that lower natriuretic peptide (NP) levels are associated with a decreased insulin sensitivity and have a causal role in the development of diabetes and have also shown that certain populations, such as African Americans, have relatively low NP levels, which may contribute to their underlying risk for insulin resistance. Since NPs play an important role in the regulation of insulin sensitivity, one can infer that relatively low NP levels are an important biological contributor to the high prevalence rates of cardiometabolic disease in African Americans. The Biobank will contain genetic information concerning the presence of gene variants that encode NPs.

Eligibility criteria: Inclusion Criteria:

* Age more than or equal to 18

Exclusion Criteria:

* Age \<18, at screening
* Employees or students associated with the Division of Cardiovascular Disease at UAB will not be recruited due to their vulnerable status and susceptibility to coercion.
* Women who are pregnant or who can become pregnant and not practicing an acceptable method of birth control.

Primary outcomes:
measure: Genetic Variants in the NPPA and NPPB gene of the Natriuretic Peptide family associated with the Cardiovascular and Metabolic Diseases
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
Study officials:
affiliation: University of Alabama at Birmingham
name: Pankaj Arora, MD, FAHA
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bajaj NS, Gutierrez OM, Arora G, Judd SE, Patel N, Bennett A, Prabhu SD, Howard G, Howard VJ, Cushman M, Arora P. Racial Differences in Plasma Levels of N-Terminal Pro-B-Type Natriuretic Peptide and Outcomes: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. JAMA Cardiol. 2018 Jan 1;3(1):11-17. doi: 10.1001/jamacardio.2017.4207.